Patent: 7,148,220
✉ Email this page to a colleague
Summary for Patent: 7,148,220
Title: | C-6 modified indazolylpyrrolotriazines |
Abstract: | The present invention provides compounds of formula I ##STR00001## and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. |
Inventor(s): | Vite; Gregory D. (Titusville, NJ), Gavai; Ashvinikumar V. (Princeton Junction, NJ), Fink; Brian E. (Princeton Junction, NJ), Mastalerz; Harold (Guilford, CT), Kadow; John F. (Wallingford, CT) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 11/143,279 |
Patent Claims: | see list of patent claims |
Details for Patent 7,148,220
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2022-12-13 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2022-12-13 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2022-12-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |